Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: A combined analysis of randomized controlled clinical trials

Current Medical Research and Opinion

Volumn 25, Issue 3, 2009, Pages 627-638

  Vakily, Majid ^a,c   Zhang, Weijiang ^b   Wu, Jingtao ^a   Atkinson, Stuart N ^a   Mulford, Darcy ^a  

^a TAKEDA PHARMACEUTICALS   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^c Takeda Pharmaceuticals Research and Development Center Inc   (United States)

Author keywords

Dexlansoprazole; Dual delayed release; Intragastric pH; Pharmacodynamics; Pharmacokinetics; PK PD modeling; Proton pump inhibitor; TAK 390

Indexed keywords

DEXLANSOPRAZOLE; LANSOPRAZOLE; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EXPOSURE; DRUG RELEASE; DRUG RESPONSE; FEMALE; GASTRIC PH MONITORING; HUMAN; MALE; METHODOLOGY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH ACID SECRETION; STOMACH PH; TECHNOLOGY; UNSPECIFIED SIDE EFFECT;

EID: 63849135186     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802693883     Document Type: Article

References (13)

1. Sachs G, Shin JM, Briving C, et al. The pharmacology of the gastric acid pump: the H+,K+ ATPase. Annu Rev Pharmacol Toxicol 1995;35:277-305
2. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997;112:1798-1810 (Pubitemid 27240763)
3. van Pinxteren B, Numans ME, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2006;3:CD002095
4. Fries JF, Murtagh KN, Bennett M, et al. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004;50:2433-2440 (Pubitemid 39062702)
5. Tytgat GN. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol 2001;13:S29-33 (Pubitemid 32601394)
6. Fass R. Proton-pump inhibitor therapy in patients with gastro-oesophageal reflux disease: putative mechanisms of failure. Drugs 2007;67:1521-1530 (Pubitemid 47267295)
7. Katsuki H, Yagi H, Arimori K, et al. Determination of R(+)- and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res 1996;13:611-615 (Pubitemid 26119066)
8. Gibaldi M, Perrier D. Kinetics of pharmacologic response. Pharmacokinetics, 2nd edn. New York and Basel: Marcel Dekker, 1982:221-265
9. Gabrielsson J, Weiner D. Pharmacodynamic concepts. Pharmacokinetic Data Analysis: Concepts and Applications. Swedish Pharmaceutical Press, 2nd edn. Stockholm, 1997:171-248
10. Bell NJV, Burger D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51:59-67
11. Yuan Y, Thabane M, Hunt RH. Does suppression of 24-hour intragastric pH predict healing of erosive esophagitis with anti-secretory treatment: a meta-analysis. Gastroenterology 2007;132:A489. Abstract
12. Katz PO, Ginsberg GG, Hoyle PE, et al. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2007;25:617-628 (Pubitemid 46255854)
13. Andersson T, Rohss K, Bredberg E, et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001;15:1563-1569 (Pubitemid 32912398)